Compare Zeria Pharmaceutical Co., Ltd. with Similar Stocks
Dashboard
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 8.92% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 8.64% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 8.92% over the last 5 years
3
Flat results in Jun 26
4
With ROCE of 9.33%, it has a attractive valuation with a 1.09 Enterprise value to Capital Employed
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 105,651 Million (Small Cap)
15.00
NA
0.00%
0.11
7.77%
0.97
Revenue and Profits:
Net Sales:
21,449 Million
(Quarterly Results - Jun 2026)
Net Profit:
885 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.77%
0%
-5.77%
6 Months
-15.14%
0%
-15.14%
1 Year
0.54%
0%
0.54%
2 Years
-18.24%
0%
-18.24%
3 Years
-1.2%
0%
-1.2%
4 Years
-2.19%
0%
-2.19%
5 Years
0.93%
0%
0.93%
Zeria Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.92%
EBIT Growth (5y)
18.15%
EBIT to Interest (avg)
23.91
Debt to EBITDA (avg)
1.74
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
0.63
Tax Ratio
24.85%
Dividend Payout Ratio
25.55%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.30%
ROE (avg)
8.64%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
1.10
EV to EBIT
11.66
EV to EBITDA
6.88
EV to Capital Employed
1.09
EV to Sales
1.42
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
9.33%
ROE (Latest)
7.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
21,448.50
19,489.80
10.05%
Operating Profit (PBDIT) excl Other Income
4,239.80
3,269.60
29.67%
Interest
132.00
121.90
8.29%
Exceptional Items
0.00
0.00
Consolidate Net Profit
885.30
1,035.00
-14.46%
Operating Profit Margin (Excl OI)
91.00%
78.00%
1.30%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 10.05% vs -9.16% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -14.46% vs -75.58% in Jun 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
89,159.30
87,311.10
2.12%
Operating Profit (PBDIT) excl Other Income
19,721.60
19,752.30
-0.16%
Interest
501.80
452.30
10.94%
Exceptional Items
0.00
-208.70
100.00%
Consolidate Net Profit
8,417.10
9,968.00
-15.56%
Operating Profit Margin (Excl OI)
138.80%
139.70%
-0.09%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 2.12% vs 15.30% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -15.56% vs 29.54% in Mar 2025
About Zeria Pharmaceutical Co., Ltd. 
Zeria Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






